Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific SIRPG bA77C3.1, CD172g, SIRP-B2, SIRPB2, SIRPgamma ENSG00000089012 Signal-regulatory protein gamma 20 1629152-1657779 CD markers, Predicted membrane proteins Evidence at protein level Melanoma:7.36e-7 (favourable), Endometrial cancer:1.05e-6 (favourable), Renal cancer:1.47e-6 (unfavourable), Head and neck cancer:2.24e-4 (favourable) Mixed Tissue enhanced lymph node: 39.4;tonsil: 26.8 appendix: 17.6 HLA-G ENSG00000204632 Major histocompatibility complex, class I, G 6 29826967-29831125 Cancer-related genes, Predicted membrane proteins Evidence at protein level CAB016158 Supported Melanoma:3.91e-5 (favourable) Expressed in all Tissue enriched 23 placenta: 14.8 duodenum,testis: 0.6 CD2 SRBC ENSG00000116824 CD2 molecule 1 116754385-116769228 CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002430, HPA003883 Supported Renal cancer:4.82e-6 (unfavourable), Endometrial cancer:1.69e-5 (favourable), Melanoma:3.97e-5 (favourable), Head and neck cancer:7.46e-5 (favourable), Cervical cancer:1.47e-4 (favourable), Breast cancer:4.36e-4 (favourable), Ovarian cancer:7.72e-4 (favourable) Expressed in all Tissue enhanced lymph node: 132.9 tonsil: 73.5 OTUD7B CEZANNE, ZA20D1 ENSG00000264522 OTU deubiquitinase 7B 1 149937812-150010676 Enzymes, Predicted intracellular proteins Evidence at protein level HPA027045 Supported Approved Nucleoplasm
Microtubules Melanoma:5.09e-5 (favourable), Endometrial cancer:7.47e-4 (favourable) Expressed in all Mixed testis: 23.5 LCK ENSG00000182866 LCK proto-oncogene, Src family tyrosine kinase 1 32251239-32286165 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA003494, CAB003816 Supported Approved Golgi apparatus Endometrial cancer:2.96e-6 (favourable), Renal cancer:2.60e-5 (unfavourable), Melanoma:5.65e-5 (favourable), Head and neck cancer:2.91e-4 (favourable) Mixed Tissue enhanced appendix: 68.8;lymph node: 127.7;tonsil: 75.1 spleen: 55.2 GNLY D2S69E, LAG-2, LAG2, NKG5, TLA519 ENSG00000115523 Granulysin 2 85685175-85698854 Predicted intracellular proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB025186, HPA058021 Supported Endometrial cancer:3.48e-5 (favourable), Melanoma:6.60e-5 (favourable), Renal cancer:1.50e-4 (unfavourable), Urothelial cancer:8.07e-4 (favourable) Expressed in all Tissue enhanced bone marrow: 153.1;endometrium: 113.5;spleen: 114.5 lung: 51.2 NFKB2 LYT-10, NF-kB2, p105, p52 ENSG00000077150 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) 10 102394110-102402529 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA008422, CAB022098, HPA023900 Supported Approved Nucleoplasm
Cytosol Renal cancer:6.69e-12 (unfavourable), Melanoma:8.45e-5 (favourable), Colorectal cancer:3.86e-4 (unfavourable) Expressed in all Expressed in all appendix: 72.8 DLGAP4 DAP4, KIAA0964, SAPAP4 ENSG00000080845 Discs, large (Drosophila) homolog-associated protein 4 20 36306336-36528637 Predicted intracellular proteins Evidence at protein level HPA054105, HPA056378 Approved Approved Nucleoplasm
Focal adhesion sites
Cytosol Liver cancer:3.73e-6 (unfavourable), Endometrial cancer:2.24e-5 (unfavourable), Melanoma:9.88e-5 (favourable), Renal cancer:2.48e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 60.9 CD3E ENSG00000198851 CD3e molecule, epsilon (CD3-TCR complex) 11 118304545-118316175 CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB000010, HPA040957, HPA043955, CAB072863, CAB072864 Supported Endometrial cancer:2.30e-6 (favourable), Renal cancer:1.12e-5 (unfavourable), Melanoma:1.18e-4 (favourable), Head and neck cancer:1.32e-4 (favourable), Cervical cancer:1.62e-4 (favourable), Breast cancer:1.72e-4 (favourable) Expressed in all Tissue enhanced lymph node: 203.4;tonsil: 118.2 appendix: 97.3 KIF3C ENSG00000084731 Kinesin family member 3C 2 25926596-25982749 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA035755 Approved Nuclear membrane
Nuclear bodies
Intermediate filaments Endometrial cancer:1.32e-5 (unfavourable), Melanoma:1.22e-4 (favourable), Renal cancer:7.57e-4 (unfavourable) Expressed in all Tissue enriched 13 cerebral cortex: 133.6 adrenal gland: 10.0 SLAMF6 CD352, KALI, KALIb, Ly108, NTB-A, NTBA, SF2000 ENSG00000162739 SLAM family member 6 1 160485030-160523262 CD markers, Predicted membrane proteins Evidence at protein level HPA051363, HPA051903 Uncertain Renal cancer:2.09e-6 (unfavourable), Head and neck cancer:7.34e-5 (favourable), Melanoma:1.25e-4 (favourable), Cervical cancer:2.78e-4 (favourable), Breast cancer:9.42e-4 (favourable), Endometrial cancer:9.53e-4 (favourable) Mixed Tissue enhanced lymph node: 71.8;spleen: 44.1;tonsil: 46.5 appendix: 28.3 NR1D1 ear-1, hRev, Rev-ErbAalpha, THRA1, THRAL ENSG00000126368 Nuclear receptor subfamily 1, group D, member 1 17 40092787-40100725 Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA007935 Uncertain Supported Nuclear bodies Melanoma:1.36e-4 (favourable), Colorectal cancer:1.94e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 37.5 PLA2G2A PLA2B, PLA2L ENSG00000188257 Phospholipase A2, group IIA (platelets, synovial fluid) 1 19975431-19980416 Enzymes, FDA approved drug targets, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA015236 Supported Uncertain Nucleus
Nucleoli Melanoma:1.49e-4 (favourable) Expressed in all Tissue enhanced colon: 111.4;rectum: 180.4;small intestine: 238.2 duodenum: 87.9 SPN CD43, GPL115, LSN ENSG00000197471 Sialophorin 16 29662979-29670876 CD markers, Predicted membrane proteins Evidence at protein level CAB002666, HPA055244 Supported Uncertain Golgi apparatus
Plasma membrane
Cell Junctions Endometrial cancer:3.08e-5 (favourable), Breast cancer:1.40e-4 (favourable), Melanoma:1.88e-4 (favourable) Expressed in all Tissue enhanced bone marrow: 38.7;lung: 33.4 lymph node: 25.8 SDC3 N-syndecan, SYND3 ENSG00000162512 Syndecan 3 1 30869467-30908761 Predicted membrane proteins Evidence at protein level HPA017087, CAB025786, HPA048085 Approved Approved Nucleoplasm
Mitochondria Renal cancer:1.71e-4 (unfavourable), Melanoma:2.36e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 136.8 CCL5 D17S136E, MGC17164, RANTES, SCYA5, SISd, TCP228 ENSG00000271503 Chemokine (C-C motif) ligand 5 17 35871491-35880793 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Renal cancer:3.61e-7 (unfavourable), Endometrial cancer:1.34e-5 (favourable), Melanoma:2.42e-4 (favourable) Expressed in all Tissue enhanced spleen: 81.8 lymph node: 69.9 CD7 GP40, LEU-9, Tp40, TP41 ENSG00000173762 CD7 molecule 17 82314868-82317602 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002594, HPA039079 Supported Renal cancer:7.75e-11 (unfavourable), Endometrial cancer:2.03e-5 (favourable), Melanoma:2.69e-4 (favourable), Cervical cancer:5.51e-4 (favourable) Expressed in all Tissue enhanced appendix: 44.8;lymph node: 42.1;spleen: 44.0 small intestine: 17.4 CXCR3 CD183, CKR-L2, CMKAR3, GPR9, IP10-R, MigR ENSG00000186810 Chemokine (C-X-C motif) receptor 3 X 71615916-71618517 CD markers, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA045942 Supported Renal cancer:1.67e-6 (unfavourable), Endometrial cancer:3.44e-6 (favourable), Melanoma:2.90e-4 (favourable), Head and neck cancer:3.35e-4 (favourable) Mixed Tissue enhanced lymph node: 18.1 spleen: 8.9 HLA-B AS ENSG00000234745 Major histocompatibility complex, class I, B 6 31353872-31357188 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB015418 Supported Melanoma:2.90e-4 (favourable) Expressed in all Mixed lung: 1245.1 SELPLG CD162, PSGL-1 ENSG00000110876 Selectin P ligand 12 108622277-108633959 Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002431 Supported Cervical cancer:1.46e-4 (favourable), Thyroid cancer:2.74e-4 (favourable), Melanoma:2.92e-4 (favourable), Renal cancer:5.86e-4 (unfavourable), Head and neck cancer:6.94e-4 (favourable) Expressed in all Mixed spleen: 86.7 WIPI1 Atg18, ATG18A, FLJ10055, WIPI49 ENSG00000070540 WD repeat domain, phosphoinositide interacting 1 17 68420948-68457513 Predicted intracellular proteins Evidence at protein level HPA007493, CAB037230 Supported Melanoma:3.11e-4 (favourable) Expressed in all Expressed in all placenta: 89.4 TNFAIP8L2 FLJ23467 ENSG00000163154 Tumor necrosis factor, alpha-induced protein 8-like 2 1 151156629-151159749 Predicted intracellular proteins Evidence at protein level HPA062742 Uncertain Vesicles Renal cancer:3.53e-7 (unfavourable), Melanoma:3.64e-4 (favourable) Expressed in all Tissue enhanced lymph node: 35.2;spleen: 39.7 appendix: 26.6 BCL3 BCL4, D19S37 ENSG00000069399 B-cell CLL/lymphoma 3 19 44747705-44760044 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002051, HPA047514 Approved Supported Nucleoplasm
Vesicles
Midbody Renal cancer:3.13e-14 (unfavourable), Melanoma:3.74e-4 (favourable), Glioma:5.58e-4 (unfavourable), Breast cancer:9.67e-4 (favourable) Expressed in all Expressed in all appendix: 30.9 CD5 LEU1, T1 ENSG00000110448 CD5 molecule 11 61102395-61127852 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB015392, CAB020308, HPA043416, HPA060839 Supported Head and neck cancer:7.41e-6 (favourable), Renal cancer:8.94e-5 (unfavourable), Endometrial cancer:9.00e-5 (favourable), Cervical cancer:9.16e-5 (favourable), Melanoma:3.93e-4 (favourable), Breast cancer:4.05e-4 (favourable) Mixed Tissue enhanced appendix: 31.0;lymph node: 43.6 tonsil: 21.1 CCL4 Act-2, AT744.1, LAG1, MIP-1-beta, SCYA4 ENSG00000275302 Chemokine (C-C motif) ligand 4 17 36103590-36105621 Cancer-related genes, Predicted secreted proteins Evidence at protein level CAB007805 Approved Endometrial cancer:1.97e-5 (favourable), Renal cancer:1.68e-4 (unfavourable), Colorectal cancer:3.54e-4 (favourable), Melanoma:3.97e-4 (favourable) Expressed in all Tissue enhanced spleen: 25.2 lymph node: 17.9 DOK2 Dok-2, p56dok-2 ENSG00000147443 Docking protein 2, 56kDa 8 21908873-21913860 Predicted intracellular proteins Evidence at protein level CAB004379 Supported Renal cancer:2.20e-4 (unfavourable), Melanoma:4.31e-4 (favourable) Expressed in all Mixed spleen: 35.6 SPOCK2 KIAA0275, testican-2 ENSG00000107742 Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2 10 72059035-72089032 Predicted secreted proteins Evidence at protein level HPA044605 Supported Uncertain Nuclear speckles Head and neck cancer:1.95e-5 (favourable), Breast cancer:4.05e-4 (favourable), Melanoma:4.72e-4 (favourable), Ovarian cancer:7.19e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 162.2;lung: 128.2 lymph node: 76.0 EGR3 PILOT ENSG00000179388 Early growth response 3 8 22687659-22693302 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA006206, CAB009373 Uncertain Uncertain Nucleus
Vesicles Breast cancer:1.83e-4 (favourable), Melanoma:4.78e-4 (favourable) Mixed Mixed gallbladder: 49.7 IDO1 IDO, INDO ENSG00000131203 Indoleamine 2,3-dioxygenase 1 8 39902275-39928444 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA023072, HPA023149, HPA027772 Supported Renal cancer:1.12e-7 (unfavourable), Ovarian cancer:3.32e-4 (favourable), Melanoma:5.27e-4 (favourable) Expressed in all Tissue enhanced placenta: 148.0 lymph node: 58.1 IKZF3 Aiolos, ZNFN1A3 ENSG00000161405 IKAROS family zinc finger 3 (Aiolos) 17 39757715-39864188 Predicted intracellular proteins, Transcription factors Evidence at protein level CAB017105, HPA024377 Supported Uncertain Plasma membrane
Cytosol Cervical cancer:6.85e-6 (favourable), Head and neck cancer:4.16e-4 (favourable), Melanoma:5.42e-4 (favourable), Renal cancer:7.38e-4 (unfavourable) Mixed Tissue enhanced lymph node: 45.2;spleen: 32.2;tonsil: 40.9 appendix: 26.4 CD27 S152, TNFRSF7, Tp55 ENSG00000139193 CD27 molecule 12 6444867-6451718 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002420, HPA038936 Supported Head and neck cancer:6.65e-7 (favourable), Renal cancer:1.19e-6 (unfavourable), Cervical cancer:3.77e-5 (favourable), Endometrial cancer:2.90e-4 (favourable), Melanoma:5.50e-4 (favourable) Expressed in all Tissue enhanced lymph node: 142.5;tonsil: 90.3 spleen: 69.5 ITGAL CD11A, LFA-1 ENSG00000005844 Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) 16 30472658-30523185 CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025011 Supported Renal cancer:2.69e-5 (unfavourable), Endometrial cancer:5.63e-5 (favourable), Head and neck cancer:3.34e-4 (favourable), Melanoma:5.57e-4 (favourable) Expressed in all Tissue enhanced lymph node: 80.1;spleen: 82.2 appendix: 54.3 TAPBP TAPA ENSG00000231925 TAP binding protein (tapasin) 6 33299694-33314387 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007066 Approved Breast cancer:2.76e-4 (favourable), Melanoma:6.29e-4 (favourable) Expressed in all Expressed in all spleen: 31.4 HCST DAP10, DKFZP586C1522, KAP10, PIK3AP ENSG00000126264 Hematopoietic cell signal transducer 19 35902480-35904377 Predicted membrane proteins Evidence at protein level CAB034435, HPA063026 Supported Uncertain Vesicles Renal cancer:1.59e-10 (unfavourable), Melanoma:6.70e-4 (favourable) Expressed in all Expressed in all bone marrow: 154.7 PGPEP1 Pcp, PGP, PGP-I, PGPI ENSG00000130517 Pyroglutamyl-peptidase I 19 18340587-18369950 Enzymes, Predicted intracellular proteins Evidence at protein level HPA035368, HPA055277 Approved Approved Golgi apparatus Renal cancer:3.71e-8 (favourable), Pancreatic cancer:1.71e-4 (favourable), Melanoma:6.80e-4 (favourable) Expressed in all Expressed in all kidney: 29.2 SNTA1 LQT12, SNT1, TACIP1 ENSG00000101400 Syntrophin, alpha 1 20 33407955-33443892 Disease related genes, Predicted intracellular proteins Evidence at protein level CAB037059 Approved Endometrial cancer:9.60e-6 (unfavourable), Pancreatic cancer:3.72e-4 (favourable), Melanoma:7.08e-4 (favourable) Expressed in all Expressed in all thyroid gland: 101.8 C15orf39 DKFZP434H132, FLJ46337 ENSG00000167173 Chromosome 15 open reading frame 39 15 75195643-75212169 Predicted intracellular proteins Evidence at protein level HPA039961, HPA041907 Uncertain Validated Cytosol Renal cancer:3.05e-4 (unfavourable), Testis cancer:6.02e-4 (unfavourable), Melanoma:7.94e-4 (favourable) Expressed in all Tissue enhanced testis: 123.9 bone marrow: 39.1 SIT1 SIT ENSG00000137078 Signaling threshold regulating transmembrane adaptor 1 9 35649295-35650950 Predicted membrane proteins Evidence at protein level HPA018506 Supported Endometrial cancer:1.94e-6 (favourable), Renal cancer:1.75e-5 (unfavourable), Head and neck cancer:1.14e-4 (favourable), Cervical cancer:6.56e-4 (favourable), Melanoma:8.17e-4 (favourable) Mixed Group enriched 5 appendix: 25.6;lymph node: 56.9;spleen: 22.3;tonsil: 30.9 urinary bladder: 6.3 SPATA2 KIAA0757, PD1, PPP1R145, tamo ENSG00000158480 Spermatogenesis associated 2 20 49903391-49915508 Predicted intracellular proteins Evidence at protein level HPA048581, HPA052224 Uncertain Approved Nucleus
Nucleoli fibrillar center Endometrial cancer:1.87e-4 (unfavourable), Thyroid cancer:4.53e-4 (unfavourable), Melanoma:9.08e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 22.4 REEP2 C5orf19, SGC32445, SPG72 ENSG00000132563 Receptor accessory protein 2 5 138439017-138446969 Disease related genes, Predicted membrane proteins Evidence at protein level HPA031813 Supported Breast cancer:7.83e-5 (favourable), Glioma:3.43e-4 (unfavourable), Melanoma:9.31e-4 (favourable) Tissue enriched Tissue enriched 5 cerebral cortex: 90.3 smooth muscle: 17.8 BCL2L1 Bcl-X, bcl-xL, bcl-xS, BCL2L, BCLX, PPP1R52 ENSG00000171552 BCL2-like 1 20 31664452-31723989 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters Evidence at protein level HPA035734, CAB072801 Approved Approved Mitochondria Renal cancer:8.89e-5 (favourable), Pancreatic cancer:5.87e-4 (unfavourable), Endometrial cancer:9.10e-4 (unfavourable), Melanoma:9.57e-4 (favourable) Expressed in all Expressed in all gallbladder: 100.9 NRTN NTN ENSG00000171119 Neurturin 19 5823802-5828324 Disease related genes, Predicted secreted proteins Evidence at protein level HPA065260 Approved Golgi apparatus Endometrial cancer:3.86e-4 (favourable), Head and neck cancer:7.23e-4 (favourable), Melanoma:9.92e-4 (favourable) Mixed Mixed heart muscle: 4.6